Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Implant in Carcinoid Syndrome
NCT00884715Phase 2Terminated
- Sponsor
- Endo International plc
- Start
- Jul 2009
- Primary completion
- Nov 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of octreotide in Carcinoid Syndrome (CS) (2 arms), sponsored by Endo International plc. Primary endpoint: Effects of 1 or 2 implants on carcinoid syndrome symptoms of flushing and diarrhea at 9 months. Started Jul 2009; status: terminated.
02
Drugs
octreotide
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT00884715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884715.